Want to see TSE:DTC full AI Analyst Report?
Defence Therapeutics (DTC) Income Statement
Defence Therapeutics Income Statement
Last quarter (Q4 2026), Defence Therapeutics's total revenue was $0.00. In Q4, Defence Therapeutics's net income was $-1.50M. See Defence Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Jun 26 | Sep 25 | Jun 24 | Sep 23 | Sep 22 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -72.11K | $ -72.34K | $ -90.92K | $ -13.82K | $ 0.00 | |
| $ 4.92M | $ 3.20M | $ 12.66M | $ 6.48M | $ 3.56M | |
| Depreciation and Amortization | $ 72.11K | $ 72.34K | $ 90.92K | $ 13.82K | $ 7.27M |
| $ -4.92M | $ -3.13M | $ -12.66M | $ -6.48M | $ 0.00 | |
| $ -4.99M | $ -3.27M | $ -12.66M | $ -6.55M | $ -3.56M | |
| $ -1.79M | $ -253.20K | $ -537.24K | $ -322.42K | $ -3.78M | |
| $ -6.78M | $ -3.52M | $ -13.19M | $ -6.87M | $ -7.34M | |
| $ -6.70M | $ -3.52M | $ -13.19M | $ -6.76M | $ -7.34M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.11 | $ -0.07 | $ -0.30 | $ -0.17 | $ -0.20 |
| Diluted EPS | $ -0.11 | $ -0.07 | $ -0.30 | $ -0.17 | $ -0.20 |
| Weighted Average Shares Outstanding | 62.18M | 49.83M | 44.63M | 39.66M | 36.08M |
| Weighted Average Shares Outstanding (Diluted) | 62.18M | 49.83M | 44.63M | 39.66M | 36.08M |
Currency in CAD
